AstraZeneca's Anselamimab Shows Kappa Subgroup Benefit in Phase III AL Amyloidosis Trial

AstraZeneca's Anselamimab Shows Kappa Subgroup Benefit in Phase III AL Amyloidosis

AstraZeneca's investigational anti-fibril therapy, anselamimab, did not achieve its primary endpoint in the overall light chain amyloidosis (AL amyloidosis) population during its global Phase III CARES program. However, a prespecified subgroup analysis of 72 patients with kappa predominant light chain isotype revealed a significant clinical benefit. In this specific group, anselamimab, when added to standard of care, improved survival by 62% (all-cause mortality) and reduced cardiovascular hospitalizations by 71%. These positive outcomes were consistent across both Mayo stage IIIa and IIIb diseases, with numerical improvements in key secondary endpoints observed at 50 weeks.

• The Phase III CARES program for anselamimab, AstraZeneca's anti-fibril therapy, did not meet its primary endpoint in the overall population of patients with AL amyloidosis. Data published in July 2025 indicated no overall benefit, with patients having the lambda isotype showing similar mortality rates (33.3% for anselamimab vs. 33.9% for placebo), highlighting the therapy's lack of broad efficacy.
• A crucial finding emerged from a prespecified subgroup analysis of 72 patients with kappa predominant light chain isotype. In this group, anselamimab demonstrated a highly clinically meaningful benefit, improving survival by 62% (all-cause mortality) and reducing the frequency of cardiovascular hospitalizations by 71% compared to placebo, when administered as first-line therapy alongside standard of care.
• The observed reduction in all-cause mortality within the kappa subgroup was consistent across different disease severities. Patients with Mayo stage IIIa disease experienced a 75% reduction in mortality risk, while those with Mayo stage IIIb disease saw a 48% reduction. Additionally, numerical improvements in key secondary endpoints, such as quality and functional capacity, favored anselamimab in kappa AL amyloidosis patients at 50 weeks.

Anselamimab's CARES Phase III Results: A Nuanced Outcome for Kappa AL Amyloidosis

The isatuximab monotherapy trial (NCT#03499808) published in 2025 demonstrated substantial clinical activity in relapsed AL amyloidosis patients. This multi-center, cooperative group phase 2 trial enrolled 43 patients who received isatuximab 20 mg/kg intravenously weekly during the first 28-day cycle, followed by biweekly administration during cycles 2-24. Among the 35 evaluable patients, the overall hematologic response rate reached 77.1%, with 57% achieving very good partial response or better. The median time to partial response or better was notably rapid at 1.1 months. Organ-specific responses were encouraging, with renal responses observed in 50% of patients with renal involvement and cardiac responses in 57% of evaluable patients with cardiac involvement based on NT-pro-BNP criteria.

A real-world matched-cohort study published in 2026 compared a frequency-adjusted, cyclophosphamide-free daratumumab-based regimen against bortezomib/dexamethasone in newly diagnosed AL amyloidosis patients. The study included 105 patients treated between January 2018 and December 2024, with 60 patients analyzed after propensity score matching. The daratumumab-based approach utilized a modified schedule with biweekly dosing in cycle 1 followed by monthly administration, with response-guided treatment duration. This strategy demonstrated significantly superior outcomes, with hematologic complete response rates of 57% versus 27% at 6 months (p=0.018) and 63% versus 27% at 12 months (p=0.002). The median time to complete response was substantially shorter at 61 versus 120 days (p=0.010), and both cardiac and renal responses were significantly improved.

The Australian Amyloidosis Network reported outcomes from 271 patients with AL amyloidosis treated with bortezomib-based chemotherapy in 2026. This cohort had a median age of 66 years, with 75% having lambda-restricted disease, 79% cardiac involvement, and 64% renal involvement. The overall hematological response rate was 82%, comprising 31% complete responses and 36% very good partial responses, with a median overall survival of 74 months. However, 8% of patients died prior to response assessment, highlighting the importance of early treatment intervention. The study identified several independent prognostic factors associated with inferior survival, including advanced cardiac disease staging, older age, and presence of autonomic neuropathy, while confirming the significant impact of achieving deep hematologic responses on long-term outcomes.

Addressing the Unmet Needs in Advanced Light Chain Amyloidosis

Light chain (AL) amyloidosis presents significant therapeutic challenges due to its rarity, complexity, and the vulnerability of affected organ systems. Current treatment approaches face substantial limitations that impact both clinical outcomes and patient quality of life. The absence of disease-specific therapies and regulatory-approved treatments creates additional barriers to optimal patient care.

• Lack of regulatory-approved therapies: No FDA-approved treatments exist specifically for AL amyloidosis, particularly in the relapsed/refractory setting, with treatment regimens often adapted from multiple myeloma protocols rather than being disease-specific

• Limited treatment efficacy: Most therapeutic approaches focus on symptom management rather than targeting the underlying disease process, with patients who achieve hematological complete response not necessarily experiencing organ response

• Poor treatment tolerability: Current treatments, including chemotherapy and stem cell transplantation, are difficult to tolerate for over half of patients and do not substantially improve quality of life for most individuals

• Diagnostic delays impacting treatment outcomes: Diagnosis is established ≥1 year after symptom onset in 37% of cases, often requiring visits to multiple physicians, which delays critical early intervention needed to prevent irreversible organ damage

• Disease complexity and heterogeneity: The multifaceted process of amyloid formation and organ targeting creates therapeutic challenges, with response variability observed between kappa and lambda light chain types and higher baseline disease burden predicting delayed hematologic response

• Absence of established salvage strategies: Despite advances in frontline daratumumab-based therapy, no standard salvage regimen or optimal timing exists for relapsed/refractory disease, creating uncertainty in treatment sequencing

Navigating the Evolving Treatment Landscape for AL Amyloidosis

The treatment landscape for light chain amyloidosis has undergone substantial transformation over the past five years, most notably with the emergence of daratumumab-based regimens as the new standard of care. The ANDROMEDA phase 3 trial validated daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) as frontline therapy, demonstrating significantly superior outcomes compared to CyBorD alone. Real-world evidence from 2018-2022 confirmed these findings, showing Dara-CyBorD achieved a 2-month hematological very good partial response rate of 60.8% versus 31.1% with CyBorD, along with higher complete response rates and reduced need for second-line therapy. This regimen has become the first FDA-approved therapy specifically for AL amyloidosis, fundamentally reshaping treatment algorithms and redefining the role of autologous stem cell transplantation.

Beyond daratumumab, several targeted therapies have emerged with promising efficacy profiles. Venetoclax has shown particular effectiveness in patients harboring the t(11;14) abnormality, inducing rapid and profound reductions in amyloid free light chains that can improve survival even at advanced disease stages. The TOURMALINE-AL1 trial, the first phase 3 study in relapsed/refractory AL amyloidosis, demonstrated that ixazomib-dexamethasone significantly prolonged time to vital organ deterioration compared to physician's choice therapy, despite not meeting its primary endpoint. Novel anti-fibril therapies including CAEL-101 and birtamimab are currently being tested in phase 3 trials, representing a paradigm shift toward directly targeting amyloid deposits rather than solely focusing on plasma cell eradication.

Treatment approaches have become increasingly risk-adapted and personalized based on cardiac involvement severity and molecular characteristics. Low-risk patients continue to benefit from autologous stem cell transplantation preceded by induction therapy, while intermediate and high-risk patients receive carefully dose-escalated bortezomib-based regimens. The pipeline remains robust with novel agents under investigation including next-generation proteasome inhibitors, immunomodulatory drugs, BCL-2 inhibitors, CAR-T cell therapy, and bispecific antibodies for patients who progress after daratumumab-based therapy. Real-world data from 2014-2021 demonstrates the impact of these advances, with median overall survival reaching 57.5 months and 12-month survival rates of 92%, though addressing daratumumab-refractory disease remains a critical unmet clinical need.

Anselamimab's Subgroup Success: A New Path for AL Amyloidosis

The recent announcement regarding anselamimab, AstraZeneca's investigational anti-fibril therapy, marks a pivotal moment in the evolving treatment landscape for light chain (AL) amyloidosis. While the drug did not achieve its primary endpoint in the overall AL amyloidosis population, a deeper dive into the data reveals a compelling story for a specific patient subgroup. In 72 patients with kappa predominant light chain isotype, anselamimab demonstrated a remarkable 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalizations. These are not just numerical improvements; they represent a significant clinical benefit in a disease where unmet needs remain substantial.

Current standard of care for AL amyloidosis primarily focuses on targeting the underlying plasma cell dyscrasia to prevent further amyloid formation. However, existing therapies largely fall short in their ability to remove the amyloid fibrils already deposited in organs, which continue to drive progressive dysfunction and high morbidity. The success of anselamimab in this specific subgroup, particularly in Mayo stage IIIa and IIIb diseases, offers a glimmer of hope that anti-fibril therapies can indeed reverse the disease's course by actively depleting these harmful deposits. This outcome could validate the entire anti-fibril therapeutic approach, potentially accelerating research and development in this promising area.

However, the path forward is not without its complexities.

• The market for a drug approved solely for a kappa predominant AL amyloidosis subgroup would be inherently limited, posing commercial challenges.

• Regulatory agencies will scrutinize an approval based on a subgroup analysis, even if prespecified, potentially requiring further evidence or specific post-marketing commitments.

• The therapeutic landscape for AL amyloidosis is becoming increasingly competitive, with other anti-fibril agents like birtamimab also advancing in clinical trials, which could further fragment market share.

Despite these considerations, anselamimab's data suggests a potential paradigm shift for a subset of AL amyloidosis patients. It underscores the importance of precision medicine in rare diseases and highlights how targeted approaches, even from broader trial outcomes, can unlock significant clinical value. The focus now shifts to how AstraZeneca will navigate the regulatory pathway and position anselamimab to address this critical unmet need, potentially offering a new lease on life for those with severe kappa predominant AL amyloidosis.